ILF2 and Miyoshi myopathy: To validate the effectiveness of ILF2 ASOs in enhancing the effect of DNA-damaging agents in vivo, we established a MM xenograft model that recapitulates the disseminated nature of MM and the features of its bone and organ metastases in humans.